Barrett’s esophagus management decisions are often based on subjective diagnoses, so better information and techniques are needed to aid in BE patient care

Exploration of a tissue systems pathology approach to predict progression in patients with non-dysplastic Barrett's esophagus.

TissueCypher better predicts presence of HGD and EAC in BE than pathologic variables, and can improve on histology to identify patients requiring therapy.

Post-test management plans were changed in 53% of patients who had risk aligned management changes concordant with a Class 1 (low risk) or Class 2 result (high risk).

TissueCypher is cost-saving after 5 years and improves patient outcomes due to improving the effectiveness of surveillance and treatment.

The individualized risk prediction test has the potential to improve the efficiency of endoscopic surveillance in BE and to enable early intervention as needed.

TissueCypher better predicts progression in BE than clinicopathologic variables, and can improve on histology as a method to risk stratify patients with BE

Analytical validation study to establish precision, dynamic range, RNA yield, reproducibility, and melanin inhibition

Assessment of the prognostic accuracy of GEP and sentinel lymph node biopsy (SLNB) tests, independently and in combination, in a multicenter cohort of 217 patients

Initial development and validation of the 23-GEP establishing a high level of sensitivity and specificity in a broad range of histopathological subtypes

Multicenter study shows clear and significant separation of risk between Class 1 and Class 2 result for DFS,DMFS, MSS, OS using Kaplan-Maier analysis.

To compare American Joint Committee on Cancer (AJCC), International Union Against Cancer (UICC), and Brigham and Women's Hospital (BWH) tumor (T) staging systems for cutaneous squamous cell carcinoma and validate BWH staging against prior data.